PDE-5 inhibitors : patients preferences
To date, multidisciplinary approach is commonly used to treat erectile dysfunction (ED), and the first line of ED pharmacotherapy, despite its multiple causes, is phosphodiesterase inhibitors of type 5 (PDE-5). They are considered an effective and well tolerated treatment option [1-4]. Concurrently, sildenafil has the largest evidence base for efficacy and safety [5]. The satisfaction of patients with ED therapy is a complex and personal matter, and there are no clearly established and reliable criteria for showing preferences when choosing a PDE-5. Adherence of patients to the PDE-5 therapy is determined not only by the erectile response and side effects, but also by how well the treatment meets the needs and expectations of patients and how it affects the relationship between the partners. This review examines the tolerability and efficacy of the various types of PDE-5 available for treating ED, with a special emphasis on the patient's preferences, and in particular on the new sildenafil orodispersible films. As an alternative route of drug administration, films quickly dissolve in the mouth [6] and have several advantages, improve sexual health and the sense of psychological well-being of patients and their partners.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2017 |
|---|---|
| Enthalten in: |
Urologiia (Moscow, Russia : 1999) - (2017), 3 vom: 14. Juli, Seite 120-126 |
| Sprache: |
Russisch |
|---|
| Beteiligte Personen: |
Efremov, E A [VerfasserIn] |
|---|
| Themen: |
BW9B0ZE037 |
|---|
| Anmerkungen: |
Date Completed 09.11.2017 Date Revised 09.11.2017 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM275186687 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM275186687 | ||
| 003 | DE-627 | ||
| 005 | 20231225005120.0 | ||
| 007 | tu | ||
| 008 | 231225s2017 xx ||||| 00| ||rus c | ||
| 028 | 5 | 2 | |a pubmed24n0917.xml |
| 035 | |a (DE-627)NLM275186687 | ||
| 035 | |a (NLM)28845950 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a rus | ||
| 100 | 1 | |a Efremov, E A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a PDE-5 inhibitors |b patients preferences |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 09.11.2017 | ||
| 500 | |a Date Revised 09.11.2017 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a To date, multidisciplinary approach is commonly used to treat erectile dysfunction (ED), and the first line of ED pharmacotherapy, despite its multiple causes, is phosphodiesterase inhibitors of type 5 (PDE-5). They are considered an effective and well tolerated treatment option [1-4]. Concurrently, sildenafil has the largest evidence base for efficacy and safety [5]. The satisfaction of patients with ED therapy is a complex and personal matter, and there are no clearly established and reliable criteria for showing preferences when choosing a PDE-5. Adherence of patients to the PDE-5 therapy is determined not only by the erectile response and side effects, but also by how well the treatment meets the needs and expectations of patients and how it affects the relationship between the partners. This review examines the tolerability and efficacy of the various types of PDE-5 available for treating ED, with a special emphasis on the patient's preferences, and in particular on the new sildenafil orodispersible films. As an alternative route of drug administration, films quickly dissolve in the mouth [6] and have several advantages, improve sexual health and the sense of psychological well-being of patients and their partners | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a PDE-5 inhibitors | |
| 650 | 4 | |a compliance | |
| 650 | 4 | |a erectile dysfunction | |
| 650 | 4 | |a sildenafil | |
| 650 | 4 | |a treatment | |
| 650 | 7 | |a Dosage Forms |2 NLM | |
| 650 | 7 | |a Phosphodiesterase 5 Inhibitors |2 NLM | |
| 650 | 7 | |a Sildenafil Citrate |2 NLM | |
| 650 | 7 | |a BW9B0ZE037 |2 NLM | |
| 700 | 1 | |a Kasatonova, E V |e verfasserin |4 aut | |
| 700 | 1 | |a Melnik, Ya I |e verfasserin |4 aut | |
| 700 | 1 | |a Nikushina, A A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Urologiia (Moscow, Russia : 1999) |d 1999 |g (2017), 3 vom: 14. Juli, Seite 120-126 |w (DE-627)NLM110630386 |x 1728-2985 |7 nnns |
| 773 | 1 | 8 | |g year:2017 |g number:3 |g day:14 |g month:07 |g pages:120-126 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2017 |e 3 |b 14 |c 07 |h 120-126 | ||